Objective-To evaluate the impact on mortality of standard Schwarz measles immunisation before 9 months ofage.
Introduction
In densely populated urban areas 5-10% of children may experience measles before the recommended age of immunisation (9 months) .' This is a great problem because acute case fatality ratios and long term morbidity and mortality are higher in these children. 25 After trials of medium dose and high dose EdmonstonZagreb measles vaccine among infants in West Africa and Mexico yielded successful antibody responses68 and clinical protection9 the Global Advisory Group of the Expanded Programme on Immunisation recommended in 1989 that in countries where measles is common before the age of 9 months children should be vaccinated at 6 months of age with high dose Edmonston-Zagreb measles vaccine. 10 Longer follow up in Guinea-Bissau and Senegal showed, however, that girls given high titre measles vaccines mainly before 9 months had higher mortality than girls who received standard Schwarz vaccine after this age." 12 The Global Advisory Group of the Expanded Programme on Immunisation therefore rescinded its recommendation of high titre measles vaccines and reintroduced the previous policy of one dose of standard Schwarz vaccine at 9 months ofage."
The experience with early high titre measles vaccination is likely to raise concerns that vaccination before 9 months could be dangerous. As this may become an impediment to the solution of the important problem of measles before the current age of immunisation, we analysed data from the early 1980s from one urban and two rural areas in Guinea-Bissau where children were vaccinated before 9 months of age. Vaccinations were offered only in annual or biannual campaigns. Different ages at vaccination among infants are therefore unlikely to reflect a selection bias. Children vaccinated before 9 months were offered reimmunisation. We compared mortality of children vaccinated before 9 months and at 9-1 1 months in these campaigns. The group vaccinated at 9-11 months may be said to represent the current policy of measles immunisation at 9 months," whereas the group vaccinated before 9 months represents the alternative two dose strategy (at 6 and 9 months) recommended by the Expanded Programme on Immunisation for areas with a high incidence ofmeasles.
Subjects and methods

BACKGROUND
The study of child health and mortality in GuineaBissau was started in 1978 in Bandim district in the capital and in some rural areas.4 15 In both Bandim and the rural areas, pregnancies, births, anthropometry, vaccinations, infections, and deaths were reported in the routine registration system.' 14 In Bandim we also gathered information on certain biological, cultural, and socioeconomic background factors in connection with the registration of births. Children were examined every third month in Bandim and every sixth month in the rural areas. When children were absent from these examinations, home visits were carried out to determine the child's whereabouts. Because of this close follow up it is unlikely that we missed any deaths among children still resident in the study areas. For children who died, information was collected from parents or other relatives on symptoms during the last illness.
MEASLES IMMUNISATION CAMPAIGNS
The initial project proposal emphasised nutritional patterns as determinants of child mortality. During the first years of the study, however, measles epidemics in both Bandim'4 and one rural area, Quinhamel,"
showed that measles infection could have an enormous impact on mortality in spite of reasonable levels of nutrition among the children. From In Bandim, where background information had been collected at the time of birth, it could be tested whether there were any major sociocultural differences between the children immunised at 4-8 and at [9] [10] [11] months (table II) . For all the biological, cultural, and socioeconomic indicators tested, the two groups had very similar results. (table IV) , the mortality ratio of one dose at 4-8 months compared with one at 9-11 months of age was slightly reduced (069 (0-46 to 1 08)). Mortality of reimmunised children was lower than the mortality of children who had received only one measles vaccine, though the difference was not significant (0 59 (0-28 to 1-27)). Hence, children vaccinated at 4-8 months and reimmunised had a mortality ratio of 0-41 (0-19 to 0 85) compared with children vaccinated only at 9-11 months.
Discussion
The three data sets from Bandim, Oio, and Quinhamel indicate that vaccination before 9 months of age combined with reimmunisation was associated with better childhood survival than one measles vaccination at 9-11 months of age. Initially, measles vaccine was the only immunisation available in Guinea-Bissau, so the effect is not due to additional health interventions provided at the same time as measles vaccination. We have previously shown that children who received measles immunisation in the initial measles vaccination campaigns in Bandim'6 and Quinhamel" had considerably better survival than the childen who did not receive measles vaccine. This difference could be due to a selection bias between those who attended immunisation sessions and those who did not. In the present analysis, comparing groups immunised at different ages, however, a simple selection bias is unlikely to be important. The children were immunised at the age they happened to be when a campaign was organised in their community. There was no indication that participation was different before and after 9 months of age (table I) . In Bandim, where information had been collected on various background factors (table II) , there were no differences between the children vaccinated at 4-8 months and 9-11 months ofage.
Since children vaccinated at different ages were likely to experience the seasons differently, we examined the impact of season on mortality. Season of birth was not significant, whereas the rainy season was associated with higher mortality than the dry season. In the multivariate analysis adjusting for both age and season at risk (table IV) , however, there was no modification in the estimate of early measles vaccination.
The children immunised before 9 months of age were more likely to be reimmunised and this could have provided more effective immunity against measles. However, the lower mortality of children immunised at 4-8 months was not related to better protection against measles and its long term consequences as there was no change in the mortality ratio when cases ofmeasles infection were excluded from the analysis.
EARLY VACCINATION
Measles immunisation strategies have been based on the assumption that vaccination before 9 months of age provides suboptimal protection against measles."8 In communities where measles is an important cause of death, vaccination at 9-11 months should provide better survival than vaccination before 9 months. An unexpected finding in the present study was that children with only one vaccination before 9 months of age tended to have better survival than children immunised after 9 months of age.
A number of other studies have suggested, however, that early measles immunisation is better than later vaccination. In a subsequent period in Bandim (1984-6) we found that mortality during two years of follow up for children vaccinated at 7-11 months of age was zero (0/70) compared with 11% (6/54) for children vaccinated at 12-23 months (p= 0*006).'9 A study from Benin reported that the protective efficacy of measles vaccination against all cause mortality was 64% (19-84%) for children vaccinated below 13 
RECOMMENDATIONS
The Global Advisory Group of the Expanded Programme on Immunisation recommended a schedule of two doses of Schwarz standard vaccine at 6 and 9 months of age only for certain groups at high risk of death from measles, such as infants in refugee camps, infants admitted to hospital, and infants affected by disaster. The relative efficacy of these strategies in terms of reducing mortality was never tested. The recent experience with reduced survival associated with early high titre measles immunisation compared with standard measles immunisation at 9-10 months of age" 12 could raise concern about the safety of measles immunisation among young infants. However, the present study provides some assurance that even when the coverage for a revaccination is low, standard measles immunisation before the recommended age of 9 months is not worse than vaccination at 9 months of age. It may in fact be more effective in reducing mortality.
Further studies of long term survival after measles immunisation at different ages and reimmunisation are warranted. Should the findings from Guinea-Bissau be replicable, they may have important implications for public health and the policy of measles immunisation.
As the antibody response is insufficient after early measles immunisation, raising the age at immunisation and relying on herd immunity to protect the youngest children has been recommended.2829 However, an early two dose measles vaccination strategy may be better in terms of reducing mortality than immunisation from 9 months of age or later. The number and timing of reimmunisation doses may need to be considered. Future assessments of the consequences of measles immunisation at different ages cannot be based exclusively on antibody responses and vaccine efficacy.
It is essential that studies are designed to evaluate the impact on total mortality.20
